RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
P/B ratio for RVL Pharmaceuticals plc (RVLP)
P/B ratio as of 2022: 1.97
According to RVL Pharmaceuticals plc's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.97. At the end of 2021 the company had a P/B ratio of 0.95.
P/B ratio history for RVL Pharmaceuticals plc from 2016 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 1.97 |
| 2021 | 0.95 |
| 2020 | 2.66 |
| 2019 | 3.19 |
| 2018 | 0.91 |
| 2017 | 0.83 |
| 2016 | 0.75 |